Oncocyte reports Q2 revenue $104K, loss $0.36/sh; launches GraftAssure at two centers

Insight Molecular Diagnostics Inc.

2024-Q2 EPS reported -$1.32 revenue$280,000

Revenue of $104K from pharma services; operating expenses $4.7M; loss from ops $4.5M ($0.36/sh).
GraftAssure RUO assay used at two transplant centers in U.S. and Southeast Asia in July 2024.
Sales funnel represents centers covering ~25% of annual U.S. transplant volumes (11,000+ transplants).
Appointed Andrea James as CFO; she previously led IR at Axon and helped raise >$550M in equity.
Cash & equivalents $11.0M at June 30, up $3.7M sequentially; includes $1.7M restricted cash.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.